(NASDAQ: RVPH) Reviva Pharmaceuticals Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.7%.
Reviva Pharmaceuticals Holdings's earnings in 2024 is -$35,508,959.On average, 2 Wall Street analysts forecast RVPH's earnings for 2024 to be -$29,071,862, with the lowest RVPH earnings forecast at -$31,009,986, and the highest RVPH earnings forecast at -$27,133,738. On average, 2 Wall Street analysts forecast RVPH's earnings for 2025 to be -$24,301,095, with the lowest RVPH earnings forecast at -$27,431,910, and the highest RVPH earnings forecast at -$21,170,279.
In 2026, RVPH is forecast to generate -$7,752,496 in earnings, with the lowest earnings forecast at -$7,752,496 and the highest earnings forecast at -$7,752,496.